Here is the synopsis of our sample research paper on The Ethics of Pricing and Access to Health Care: A Social Justice Issue. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
Tihs 20 page paper provides an overview of the social justice issue of pharmaceutical pricing and the impacts on access to health care. Bibliography lists 15 sources.
Page Count:
20 pages (~225 words per page)
File: MH11_MHPharmethics.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
as a natural part of the commitment of the government to its people. In the United States, though, the focus on pharmaceutical development has led to a kind of
"free-for-all" in the industry, where each company strives to produce new products at an alarming rate, with the end goal of profitability and competitive advantage. Who pays for these
medical advancements? Who pays for new drug research, development and distribution? Though pharmaceutical conglomerates produce thousands of new drug products every year and distribute them throughout the world,
the United States pays the lions share of the cost to bring these new products to the worlds medicine cabinets. With prescription drug costs on the rise, many Americans living
at or below the poverty level find themselves out of the loop of the necessary products needed to ensure their health. Because there is a disproportionate amount of illness
among the nations poor, these individuals are the hardest hit by pharmaceutical drug price increases. The question this raises, then, is whether pharmaceutical industry pricing and the impact that
it has on access to health care reflects ethical business practices. From a social justice perspective, then, the application of ethical philosophies can be used to understand the overall
problem of expansive pharmaceutical pricing and the social impacts for the nations poor. The Scope of the Problem One of the most difficult problems in the modern health
care environment is that even when effective treatments are available, not everyone can afford them. "Total outlays on healthcare products and services hit $1.6 trillion in 2002--nearly 15% of
the nations total economic output" (Wechsler, 2004, p. 16). Many medical programs provide diagnostic services, testing and even support service, but do not cover expensive prescription drugs. Many
...